

## Disclosures

### Personal Commercial (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
caremark	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Corvista	Consultant Fees/Honoraria	Modest (< \$5,000)	
Gossamer Bio	Research/Research Grants	Significant (>= \$5,000)	
Gossamer Bio	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
United Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>

### Additional Personal Commercial Disclosures for Education Activities (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Inhibikase	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Keros	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Liquidia	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Pulmovant/Roivant	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Respira	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>

### Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Keros	Research/Research Grants	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Liquidia	Research/Research Grants	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

## Agreement

---

### **Certified Education Attestation** | Signed on 5/29/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 5/29/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### **Embargo** | Signed on 5/29/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### **On-Going Obligation Agreement** | Signed on 5/29/2025

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.